Results 41 to 50 of about 12,164 (196)

Revisiting the question of pemphigus classification

Vestnik Dermatologii i Venerologii, 2021
Analysis of various classifications of pemphigus shows that there are no fundamental differences between them. The main distinctions consist in use of diverse terms in naming of some forms of pemphigus and in inclusion or exclusion of certain subtypes ...
Alexey V. Samtsov, Evgeny V. Sokolovskiy, Natalia P. Teplyuk, Irena E. Belousova, Muza M. Kokhan, Elena V. Matushevskaya   +5 more
doaj   +1 more source

A case of concomitant pemphigus foliaceus and oral pemphigus vulgaris [PDF]

, 2018
Pemphigus is a chronic autoimmune condition that can affect multiple areas of the body. The two main subtypes of pemphigus are pemphigus vulgaris (PV) and pemphigus foliaceus (PF) which can rarely occur concurrently or even transition from one to the ...
Hegarty, A.M., Ruth Murphy, Murphy, R., Farthing, P.M., Alexandra C. Perks, Perks, A.C., Anne M. Hegarty, Paula M. Farthing   +7 more
core   +1 more source

Transition of Pemphigus Vulgaris to Pemphigus Foliaceus Due to Non-Drug Substances [PDF]

, 2020
Pemphigus is an auto-immune bullous disease which includes subgroups such as; Vulgaris, Foliaceus, and others. Pemphigus disease is characterized by bullous lesions and erosions of the skin and mucosae.
Daye, Munise, Cihan, Sultan Gamze, Durmaz, Koray, Findik, Siddika   +3 more
core   +1 more source

Data on HLA class I/II profile in Brazilian pemphigus patients

Data in Brief, 2016
Pemphigus are blistering autoimmune diseases related with genetic and environmental factors. Here we describe HLA genotyping in pemphigus patients. First, we review the HLA class I/II data on pemphigus reported in Brazilian samples and then present the ...
Maria José Franco Brochado, Daniela Francisca Nascimento, Neifi Hassan Saloum Deghaide, Eduardo Antonio Donadi, Ana Maria Roselino   +4 more
doaj   +1 more source

Epidemiology of Pemphigus

JID Innovations, 2021
Pemphigus is an epidemiologically heterogeneous group of autoimmune bullous diseases comprising pemphigus vulgaris (PV), pemphigus foliaceus, paraneoplastic pemphigus, IgA pemphigus, and pemphigus herpetiformis.
Khalaf Kridin, Enno Schmidt
doaj   +1 more source

Annular Neutrophilic Variant of Pemphigus Foliaceus

Przegląd Dermatologiczny
Pemphigus belongs to autoimmune blistering disorders involving circulating antibodies against desmogleins, the proteins involved in keratinocyte adhesion.
Vasudha Belgaumkar, Janhvi Shinde, Shekhar Pradhan, Kiran Dange, Neelam Bhatt, Sarthak Varshney   +5 more
doaj   +1 more source

Pemphigus foliaceus ehk lehtketendav villtõbi. Haigusjuhu kirjeldus ja ülevaade [PDF]

, 2019
Pemphigus foliaceus on pemfiguse rühma haiguste alla kuuluv, peamiselt täiskasvanueas harva esinev villiline dermatoos. Haigusele on iseloomulik desmogleiin 1 vastaste autoantikehade teke, millest tingituna katkevad keratinotsüütidevahelised sidemed ja ...
Karelson, Maire, Pohla, Liis
core   +1 more source

Pemphigus Vulgaris and Pemphigus Foliaceus Antibodies are Pathogenic in Plasminogen Activator Knockout Mice

, 1999
Previous studies have suggested that urokinase plasminogen activator is required for blister formation in pemphigus vulgaris and pemphigus foliaceus.
Stanley, John R., Wang, Zhi Hong, Mahoney, My G.   +2 more
core   +1 more source

Real World Use of the IL‐36 Receptor Antagonist Spesolimab: A Systematic Review and Analysis

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Spesolimab, an interleukin‐36 receptor antagonist, is approved for the treatment and prevention of generalised pustular psoriasis (GPP) flares. Its use has increasingly been reported in real‐world settings for both GPP and other inflammatory dermatoses.
Sophia A. Mense, Nicole Bavaro, Aashna Farishta, Jiaqi Chen, Raj Chovatiya   +4 more
wiley   +1 more source

Real‐World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Rituximab is endorsed internationally as first‐line therapy for moderate‐to‐severe pemphigus, but Australian guidelines position it as a rescue agent and local outcome data are limited. In this single‐centre retrospective cohort, 24 adults with pemphigus vulgaris (n = 16) or pemphigus foliaceus (n = 8) received rituximab as part of routine ...
Pokphazz Christjaroon, Ali Abid, Orli Wargon, Paul Weller, Artiene Tatian   +4 more
wiley   +1 more source